Drug Profile
Research programme: Nrf2 activators - Cureveda/GlaxoSmithKline
Alternative Names: VEDA-1209Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cureveda; GlaxoSmithKline
- Developer Cureveda; Georgia State University; GSK; Johns Hopkins University; Temple University
- Class Small molecules
- Mechanism of Action NF E2 related factor 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Multiple sclerosis; Radiation injuries; Ulcerative colitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Ulcerative-colitis in USA
- 04 Nov 2017 No recent reports of development identified for research development in Multiple-sclerosis in USA
- 04 Nov 2017 No recent reports of development identified for research development in Radiation-injuries in USA